New medication also reduces by 40 percent the number of pulmonary exacerbations, the leading cause of death in cystic fibrosis patients
Results from two phase 3 clinical trials published today in the New England Journal of Medicine show that a new combination of medications can successfully treat the underlying cause of cystic fibrosis for patients age 12 and older with two copies of the F508del gene mutation – the most common form of the life-threatening, genetic disease found in over half of the cystic fibrosis (CF) population. Approximately 8,500 people in the U.S., and 22,000 people in North America, Europe and Australia, age 12 and older with cystic fibrosis carry this gene mutation.
The international trial, which studied more than 1,000 cystic fibrosis patients age 12 and older, revealed that a combination of the drugs Kalydeco (ivacaftor) and lumacaftor, an experimental drug that has not yet been approved by the Food and Drug Administration (FDA), successfully treated the defective CF protein and improved lung function. The drugs also helped patients achieve a 40 percent reduction in pulmonary exacerbations, the leading cause of death in cystic fibrosis patients.
“Being able to treat not just the symptoms, but the underlying cause of cystic fibrosis by targeting this specific gene mutation, is a major game changer because it is by far the most common in patients with this disease,” said Dr. Bonnie Ramsey, director of the Center for Clinical and Translational Research at Seattle Children’s Research Institute and professor of Pediatrics at the University of Washington, who presented the study’s findings at the Center for Drug Evaluation and Research advisory committee meeting on May 12. “Previously, we found that Kalydeco treated just four percent of cystic fibrosis patients, but this new combination treats the defective CF protein for a much greater number of patients.”
The drugs, which work together to address the defective gene mutation by allowing the proteins within the cell to fold properly, reach the cell surface and then work as a salt channel, were given to patients over the course of 24 weeks in an effort to gain insight on how they may improve lung function and quality of life for people living with cystic fibrosis.
The trial included cystic fibrosis patients from Seattle Children’s and the University of Washington Medical Center. Today, the median predicted age of death for a person with the disease is in the mid-20s.
“What gives me tremendous confidence and excites me the most are the comprehensive health improvements seen in patients across all age groups, in all geographies and with all levels of disease severity,” said Ramsey, who was one of four lead authors on the trial and is a pioneer in cystic fibrosis treatment. “Patients can now have longer periods of good health, greatly improving their quality of life.”
The Latest on: Cystic Fibrosis
via Google News
The Latest on: Cystic Fibrosis
- For people with cystic fibrosis, COVID-19 fear amplifiedon March 24, 2020 at 1:06 am
Chloe Lussier-Labelle, 30, has cystic fibrosis and is worried what might happen if she gets COVID-19. (Supplied by Lussier-Labelle) Chloe Lussier-Labelle says her doctor has been upfront with her. If ...
- Coronavirus medic moves out of her home to protect husband with cystic fibrosis as she begs Brits to stay insideon March 23, 2020 at 9:54 am
AN NHS worker whose husband suffers with respiratory condition cystic fibrosis has pleaded for Brits to stay inside - and says she's moving out to protect him. Jenny Hawkins, who works at the Royal ...
- Parade thrown for Clarksville boy with cystic fibrosis who tested positive for coronaviruson March 23, 2020 at 3:34 am
Students and their parents are showing support for a six-year-old Clarksville boy with a compromised immune system who tested positive for the novel coronavirus last week.
- BRAUN: Coronavirus chaos like any regular day for people with cystic fibrosison March 22, 2020 at 1:00 pm
If the fear and anxiety don’t kill you first. That’s the new reality of COVID-19 — or just a regular day if you have cystic fibrosis. God willing, there will be a vaccine against coronavirus ...
- P.E.I. woman with cystic fibrosis needs Islanders' help to stay healthyon March 21, 2020 at 3:06 am
A P.E.I. woman who lives with cystic fibrosis is hoping Islanders will heed the warnings and recommendations of chief public health officer Dr. Heather Morrison. The current global pandemic has ...
- 6-year-old Clarksville boy with cystic fibrosis tests positive for coronaviruson March 21, 2020 at 12:33 am
MONTGOMERY COUNTY, Tenn. (WKRN) — A six-year-old elementary school student in Clarksville with a compromised immune system has tested positive for the novel coronavirus, according to his mother.
- 6-year-old Clarksville child with cystic fibrosis now has COVID-19on March 20, 2020 at 10:48 pm
is a pandemic. Reported illnesses range from very mild to severe, including death. Agencies anticipate widespread transmission will occur in the U.S. in coming months and recommend social distancing ...
- Our kids have cystic fibrosis. We've been practicing coronavirus health hygiene for years.on March 20, 2020 at 3:55 am
The coronavirus pandemic will end, but at-risk populations will still be vulnerable. We hope proper health hygiene will not disappear with the virus.
- Cystic fibrosis: Gravely ill mother, 32, gets wonder drug through Daily Express pleaon March 20, 2020 at 3:12 am
A GRAVELY ill mother has managed to secure a life-saving cystic fibrosis wonder drug after her plea through the Daily Express was answered.
- Cystic fibrosis patients are meant to stay six feet apart. But these sisters are inseparableon March 19, 2020 at 2:29 pm
It's because of the "six-foot rule" — an everyday medical protocol that says people with cystic fibrosis (CF) should stay at least six feet, or two metres, away from each other. It's so they don't ...
via Bing News